This image is not available for purchase in your country.

Rituximab drug molecule

Rituximab drug molecule

A617/0222

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

DR MARK J. WINTER / SCIENCE PHOTO LIBRARY DR MARK J. WINTER / SCIENCE PHOTO LIBRARY

Caption

Rituximab drug molecule. Computer model showing the secondary structure of the drug rituximab (marketed as MabThera). The primary structure of an oligosaccharide (sugar) is at upper left. Oligosaccharides are necessary for the biological activity of proteins. Rituximab is a monoclonal antibody that binds to CD20 receptors on the surface of B cells (white blood cells), flagging them for destruction by the immune system. It is used to treat rheumatoid arthritis, which is caused by the immune system attacking the body's own tissues. By reducing the number of B cells, symptoms can be reduced. It is also used to treat B cell non-Hodgkin's lymphoma and B cell leukaemia as it clears cancerous B cells from the blood, allowing them to be replaced with healthy cells.

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}